Epitomee Medical Ltd

Tel Aviv Stock Exchange EPIT.TA

Epitomee Medical Ltd Capital Expenditure for the year ending December 31, 2023: USD -1.12 M

Epitomee Medical Ltd Capital Expenditure is USD -1.12 M for the year ending December 31, 2023, a -6.77% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Epitomee Medical Ltd Capital Expenditure for the year ending December 31, 2022 was USD -1.05 M, a -712.28% change year over year.
  • Epitomee Medical Ltd Capital Expenditure for the year ending December 31, 2021 was USD -129.37 K, a -299.96% change year over year.
  • Epitomee Medical Ltd Capital Expenditure for the year ending December 31, 2020 was USD -32.35 K, a 7.51% change year over year.
  • Epitomee Medical Ltd Capital Expenditure for the year ending December 31, 2019 was USD -34.97 K.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
SV Wall Street
Tel Aviv Stock Exchange: EPIT.TA

Epitomee Medical Ltd

CEO Dr. Radan Hashimshony Ph.D.
IPO Date Dec. 15, 2021
Location Israel
Headquarters 19 Tarshish
Employees 42
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. Its capsule is used for weight management, waist circumference reduction, and cardiovascular risk factors reduction. Epitomee Medical Ltd has a strategic partnership with Nestlé Health Science S.A. for the development and commercialization of the weight loss capsule. The company was incorporated in 2005 and is based in Caesarea, Israel.

StockViz Staff

January 29, 2025

Any question? Send us an email